As­traZeneca’s triplet with Imfinzi, treme and chemo works on a key end­point for front­line lung can­cer

As­traZeneca’s big come­back year just got bet­ter.

Af­ter dis­ap­point­ing in­vestors with re­peat­ed set­backs on their PD-L1/CT­LA-4 matchup of Imfinzi and treme­li­mum­ab, the phar­ma gi­ant said Mon­day that the com­bo — com­bined with a choice of chemother­a­pies — worked in de­lay­ing dis­ease pro­gres­sion in front­line cas­es of Stage 4 non-small cell lung can­cer, hit­ting a key end­point in the close­ly-watched PO­SEI­DON study. And on the pri­ma­ry, Imfinzi and chemo to­geth­er al­so hit on the pro­gres­sion-free sur­vival yard­stick.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER